Verona Pharma PLC American Depositary Share (VRNA) Projected to Post Quarterly Earnings on Thursday

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) is expected to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Verona Pharma PLC American Depositary Share to post earnings of $0.39 per share and revenue of $68.24 million for the quarter.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last released its earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.14. The firm had revenue of $103.14 million during the quarter, compared to analysts’ expectations of $90.41 million. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. On average, analysts expect Verona Pharma PLC American Depositary Share to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Verona Pharma PLC American Depositary Share Stock Down 0.0%

VRNA stock opened at $105.24 on Tuesday. The stock has a market capitalization of $8.96 billion, a P/E ratio of -106.30 and a beta of 0.12. The company has a debt-to-equity ratio of 0.87, a quick ratio of 10.54 and a current ratio of 10.71. Verona Pharma PLC American Depositary Share has a one year low of $22.50 and a one year high of $105.50. The company has a 50 day moving average price of $97.62 and a two-hundred day moving average price of $76.18.

Analyst Ratings Changes

VRNA has been the subject of several research reports. Canaccord Genuity Group cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and set a $107.00 price objective for the company. in a research note on Wednesday, July 9th. BTIG Research cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Roth Capital cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Cowen cut shares of Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a research note on Wednesday, July 9th. Finally, Wells Fargo & Company cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and lowered their price objective for the company from $138.00 to $107.00 in a research note on Thursday, July 10th. Eleven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $109.00.

Insider Activity

In other Verona Pharma PLC American Depositary Share news, CFO Mark W. Hahn sold 208,912 shares of the business’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a total value of $2,745,103.68. Following the transaction, the chief financial officer owned 12,464,968 shares in the company, valued at $163,789,679.52. The trade was a 1.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Kathleen A. Rickard sold 58,336 shares of the business’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $766,535.04. Following the completion of the transaction, the insider owned 2,607,472 shares in the company, valued at $34,262,182.08. This represents a 2.19% decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,220,584 shares of company stock worth $24,613,268 in the last quarter. Insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Verona Pharma PLC American Depositary Share

A number of institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its holdings in Verona Pharma PLC American Depositary Share by 274.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,041,408 shares of the company’s stock worth $66,119,000 after buying an additional 763,353 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Verona Pharma PLC American Depositary Share by 18.7% in the 2nd quarter. Geode Capital Management LLC now owns 68,430 shares of the company’s stock valued at $6,472,000 after purchasing an additional 10,757 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Verona Pharma PLC American Depositary Share by 43.3% in the 1st quarter. Royal Bank of Canada now owns 9,719 shares of the company’s stock valued at $617,000 after purchasing an additional 2,938 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in shares of Verona Pharma PLC American Depositary Share in the 1st quarter valued at about $58,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Verona Pharma PLC American Depositary Share in the 1st quarter valued at about $48,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.